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ABSTRACT: Because breast cancer patient survival inversely
correlates with metastasis, we engineered vehicles to inhibit
both the C-X-C chemokine receptor type 4 (CXCR4) and
lipocalin-2 (Lcn2) mediated migratory pathways. pH-respon-
sive liposomes were designed to protect and trigger the release
of Lcn2 siRNA. Liposomes were modiﬁed with anti-CXCR4
antibodies to target metastatic breast cancer (MBC) cells and
block migration along the CXCR4-CXCL12 axis. This
synergistic approachcoupling the CXCR4 axis blockade
with Lcn2 silencingsigniﬁcantly reduced migration in triple-
negative human breast cancer cells (88% for MDA-MB-436 and 92% for MDA-MB-231). The results suggested that drug
delivery vehicles engineered to attack multiple migratory pathways may eﬀectively slow progression of MBC.
KEYWORDS: CXCR4, liposome, siRNA, breast cancer, lipocalin-2, migration
■ INTRODUCTION
Metastatic breast cancer (MBC) is the second leading cause of
cancer-related fatality in women, accounting for more than
40,000 deaths each year.
1 MBC has a ﬁve-year relative survival
rate of 23% compared with 99% for patients with nonmetastatic
breast cancer.
1 These statistics suggest an urgent and signiﬁcant
need for developing novel and eﬃcient therapeutics for the
treatment of MBC.
A principal challenge in MBC treatment is to determine how
to block MBC cell migration.
2 While many cancer therapies focus
on cytotoxicity and targeting, few address migration, which inversely
correlates with patient survival.
3 Ideally, an eﬀective drug delivery
strategy would possess multiple functions, including targeting,
triggering delivery, and eﬃciently reducing MBC cell migration.
Although human epidermal growth factor receptor 2 (HER2)
targeted therapeutics (trastuzumab,
4 lapatinib,
5 and neratinib
6)
have signiﬁcantly improved the HER2 positive breast cancer
prognostic outcome, HER2+ breast cancers comprise only
approximately 20−25% of all breast cancers.
7 A variety of other
receptors (e.g., transferrin receptor and epidermal growth factor
receptor) are under intense investigation for targeting breast
tumors;
8,9 their application is hindered by their expression on a
number of normal tissues. An eﬀective therapeutic target would
have diﬀerential expression in breast cancer and normal tissues
and be broadly identiﬁed on a range of breast cancers.
C-X-C chemokine receptor type 4 (CXCR4 or CD184) has
been investigated extensively due to its potential role in metastasis.
10
CXCR4 is a G protein-coupled receptor that plays an important
role in chemosensory transduction mechanisms in leukocytes
and hematopoietic stem cells. It regulates cell migration along
chemokine gradients, toward stromal derived factor 1 (SDF1 or
CXCL12).
11 When CXCR4 is stimulated by its ligand SDF-1,
CXCR4 couples with Gi family proteins and activates a number of
signaling pathways involved in a variety of biological responses.
12
For example, CXCR4 ligand binding can lead to activation of PI3K
and Rho family gtpases involved in the regulation of chemotaxis
and survival.
12 Each of these molecules plays a primary role in
MBC. CXCR4’s role in cancer metastasis is conﬁrmed by CXCR4
silencing and inhibition.
10
In addition to receptor inhibition, we hypothesized that
silencing of lipocalin-2 (Lcn2) at the same time would
synergistically hinder cell migration. Lcn2, also referred to as
neutrophil gelatinase-associated lipocalin (NGAL), is a secreted
protein that is a member of the lipocalin protein superfamily.
Increased Lcn2 levels have been reported in a variety of human
epithelial cancers, including breast, ovarian, colon, pancreatic,
and thyroid.
13 In breast cancer, high Lcn2 levels were
associated with poor patient prognosis and advanced cancer
status. Lcn2 is recognized as an independent prognostic marker
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14 We have previously shown that Lcn2
induced the epithelial to mesenchymal transition (EMT) in breast
cancer cells and the knockdown of Lcn2 decreased breast cancer
cell migration and invasion.
15 Consistent with our ﬁndings,
deﬁciency of Lcn2 reduced tumor growth and metastasis in a
transgenic mouse model of breast cancer.
16 For these reasons, we
chose Lcn2 as a second target to inhibit metastasis.
Small interfering RNA (siRNA) is able to induce the
destruction of speciﬁc mRNA sequences, altering the behavior
of diseased cells. siRNA-induced protein regulation has shown
therapeutic beneﬁts in breast cancer.
17 The major stumbling
block for the clinical siRNA therapy is its delivery to target cells.
The short half-life (t1/2 ∼1.5 min
18) of siRNA in blood and
need for intracellular delivery are challenges for translation to
the clinic. A variety of methods have been developed to deliver
siRNA, including direct intravenous injection of “naked” or
chemically stabilized siRNA,
19,20 packaging of siRNA into DNA
plasmid vectors,
21,22 transposon vectors (transgenic plas-
mids),
23 plasmid-infected viruses,
24 virosomes (reconstituted
viral envelopes),
25 lentiviral vectors,
26,27 and liposomes.
28 We
have previously demonstrated that pH-responsive liposomes
are advantageous for delivering siRNA, because they not only
improve pharmacokinetics but also provide a stable shield from
enzyme degradation.
29
In this report, we hypothesized that a synergistic treatment
coupled CXCR4 axis blockade and Lcn2 silencing could inhibit
MBC cell migration more eﬃciently than either one of these
treatments alone. The role of CXCR4 in our drug delivery
system is 2-fold: (1) targeting CXCR4 overexpression on breast
cancer cells, which may enhance therapeutic binding, and (2)
inhibiting MBC metastasis by blocking the CXCR4 chemokine
axis.
30 Targeting and inhibition of CXCR4 together with
pH-triggered delivery of Lcn2 siRNA may be achieved in one
vehicle. This multitargeted approach, which obstructs two
migratory pathways, may be a novel and powerful strategy for
inhibiting MBC migration.
■ EXPERIMENTAL SECTION
Materials. 1,2-Dioleoyl-3-dimethylammonium-propane
(DODAP), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-
N-dodecanoyl (N-dod-PE) were obtained from Avanti Polar
Lipids (Alabaster, AL). Immunoglobulin G (IgG) isotype control,
mouse anti-human CXCR4 monoclonal antibody (aCXCR4), and
NorthernLight 557 (NL557)-conjugated donkey anti-mouse IgG
were purchased from R&D Systems (Minneapolis, MN). Triton
X-100, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydro-
chloride (EDC), N-hydroxysuccinimide (NHS), bovine serum
albumin (BSA), rhodamine-B isothiocyanate-conjugated dextran
(rhodamine-dextran, 10 kDa MW), anhydrous dimethyl sulfoxide
(DMSO), and ethanol (EtOH) were purchased from Sigma-
Aldrich (St. Louis, MO). Phycoerythrin (PE)-conjugated mouse
anti-human CXCR4 antibody (PE-aCXCR4) and PE-conjugated
mouse IgG isotype (PE-IgG) were purchased from BioLegend
(San Diego, CA). Formaldehyde was obtained from EMD
Chemicals (Gibbstown, NJ). Dulbecco’sp h o s p h a t eb u ﬀered saline
(PBS), 0.25% trypsin/2.6 mM ethylenediaminetetraacetic acid
(EDTA) solution, human CXCR4 Taqman gene expression assay
(Hs.593413), Gibco Dulbecco’sm o d i ﬁed Eagle medium
(DMEM), GibcoDMEM/F12(1:1), 4′,6-diamidino-2-phenylin-
dole (DAPI), Quant-iT RNA Assay Kit, Lipofectamine RNAiMAX
Transfection Reagent, and CellTracker Green CMFDA (5-chloro-
methylﬂuorescein diacetate) were purchased from Invitrogen
(Carlsbad, CA). Leibovitz’s L-15 Medium and Roswell Park
Memorial Institute (RPMI)-1640 Medium were obtained from
ATCC (Manassas, VA). Lab-Tek II Chamber Slide System was
obtained from Thermo Fisher Scientiﬁc (Pittsburgh, PA).
Nuclepore track-etched membrane (pore size: 100 nm) was
obtained from Whatman (Florham Park, NJ). FLOAT-A-LYZER
G2 dialysis tubing (MWCO 300 kDa) was purchased from
Spectrum Laboratories (Rancho Dominguez, CA). Slide-A-Lyzer
dialysis cassette (MWCO 20 kDa) was obtained from Pierce
Biotechnology (Rockford, IL). Quantum Simply Cellular microbe-
ads were purchased from Bangs Laboratory, Inc. (Fishers, IN).
Dojindo cell counting kit was purchased from Dojindo Molecular
Technologies (Rockville, MD). Diﬀ-Quik Stain Set was purchased
from Siemens Healthcare Diagnostics (Tarrytown, NY). Fluorogel
with tris buﬀer was purchased from Electron Microscopy Sciences
Inc. (Hatﬁeld, PA).
Cell Culture. HCC1500, MDA-MB-175VII, MDA-MB-436,
MDA-MB-231, and MCF10A were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and cultured
in RPMI-1640 medium, Leibovitz’s L-15 medium, DMEM, and
DMEM/F12(1:1) medium with supplements, respectively. All
cells were cultured in a 37 °Ch u m i d i ﬁed incubator with 5% CO2.
The Sequence of Lcn2 siRNA. siGENOME SMARTpool
human Lcn2 siRNA constructs and siGENOME Non-Targeting
siRNA Pool were purchased from Dharmacon (Lafayette, CO).
Lcn2 siGENOME SMARTpool siRNA is composed of four Lcn2
siRNAs: D-003679-05, UGGGCAACAUUAAGAGUUA;
D-003679-03, GAAGACAAGAGCUACAAUG; D-003679-02,
GGAGCUGACUUCGGAACUA; D-003679-01, GAGCUG-
ACUUCGGAACUAA.
Quantiﬁcation of CXCR4 and Lcn2 Gene Expression.
RNA was collected with the Qiagen RNeasy minikit and
quantiﬁed by a SpectraMaxPlus 384 UV−visible spectropho-
tometer (Molecular Devices Corp, Sunnyvale, CA). The PCR
was performed by using a StepOnePlus Real-Time PCR System
(Applied Biosystems, Carlsbad, CA). All PCR samples were
referenced to the gene expression of glyceraldehyde 3-phosphate
dehydrogenase (GAPDH).
Quantiﬁcation of CXCR4 Surface Expression. Breast
cancer cell CXCR4 surface expression was quantiﬁed by using
Quantum Simply Cellular microbeads with the manufacturer’s
protocol. 106 cells were harvested and rinsed twice, and 1%
bovine serum albumin (BSA) in PBS solution was used to block
the cells for 30 min in an ice bath. Then cells were stained with
PE-aCXCR4 antibody for 1 h at RT. After antibody staining,
cells were rinsed with 1% BSA in PBS three times, resuspended
in PBS, and evaluated by a BD FACSCalibur Flow Cytometer
(BD Biosciences, San Jose, CA).
CXCR4 Immunoﬂuorescent Staining. 2 × 105 cells were
seeded in a Lab-Tek II Chamber Slide System overnight. Then
cells were ﬁxed with 4% formaldehyde in PBS at RT for 10 min
and blocked with 1% BSA in PBS for 30 min in an ice bath.
Resulting ﬁxed cells were stained with mouse anti-human
CXCR4 primary antibody and NorthernLight 557 conjugated
goat anti-mouse secondary antibody, sequentially. DAPI was used
to stain the cell nucleus. Fluorogel with tris buﬀer was used to
mount the samples. Samples were examined under a Leica TCS
SP5 confocal ﬂuorescent microscope (Leica Microsystems, Buﬀalo
Grove, IL).
CXCR4-Targeted, siRNA Encapsulating Liposome
Preparation. DOPC, DODAP, and N-dod-PE were mixed at
a mole ratio of 65:30:5 and dried in a rotary evaporator.
Resulting 5 μmol thin ﬁlm was redissolved in 1 mL of
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15 μg/mL siGENOME SMARTpool human Lcn2 siRNA or
siGENOME Non-Targeting siRNA (scrambled siRNA) in PBS
(pH 7.4). After 10 freeze−thaw cycles, lipid solution was
extruded via a NorthernLipids Extruder with a 100 nm
polycarbonate nanoporous membrane. Obtained liposome
solution was dialyzed in PBS using a Slide-A-Lyzer dialysis
cassette (MWCO 20 kDa) overnight at RT.
2 mg of EDC and 3 mg of NHS were incubated with 1 mmol
of lipid (liposomes) in PBS for 6 h at RT. A Slide-A-Lyzer
dialysis cassette (MWCO 20 kDa) was used to remove
unreacted EDC and NHS from the liposome solution. Then,
aCXCR4 or the IgG control was added to EDC-modiﬁed
liposomes at a molar ratio of 1:1000 (antibody:phospholipid)
and incubated overnight at RT. Unreacted antibodies were
removed by 24 h dialysis using a FLOAT-A-LYZER G2 dialysis
tubing (MWCO 300 kDa). aCXCR4-labeled, rhodamine-
dextran encapsulating liposomes (aCXCR4-RD-pHs) were
also produced for liposome binding studies. Its preparation
process is similar to that of aCXCR4-Lcn2-pHs except that
1 mL of lipid solution was added to a 9 mL rhodamine-dextran
solution (1 mg/mL). Lcn2 siRNA encapsulated Lipofectamine
(Lcn2-LIPO) was prepared using the manufacturer’s protocol
and used as a positive control.
aCXCR4 density on liposomes was quantiﬁed by borosilicate
bead assay. 2 μm borosilicate beads were coated with a layer of
lipids from liposomes by sonicating small unilamellar liposomes
with microbeads in PBS for 6 h. PE-aCXCR4 or PE-IgG
(nonspeciﬁc binding) was conjugated to liposome coated
microbeads using the same EDC/NHS chemistry. aCXCR4
surface density on each microbead was evaluated by ﬂow
cytometry following a similar protocol for CXCR4 cell surface
expression quantiﬁcation. Dynamic light scattering was used to
measure the liposome size and zeta potential with a Zeta-PALS
analyzer (Brookhaven Instruments, Holtsville, NY) in PBS
(pH 7.4).
siRNA Encapsulation Eﬃciency. A Quant-iT RiboGreen
RNA assay (Invitrogen, Carlsbad, CA) was performed to
determine the encapsulation eﬃciency of siRNA within the
liposome samples by using the manufacturer’s protocol. A
siRNA concentration calibration curve was generated from a
series of serially diluted siRNA standard solutions and
appropriate backgrounds measured on a SpectraMaxPlus 384
UV−visible spectrophotometer (excitation 500 nm, emission
525 nm). Then a 20 μL liposome sample was added to 1 mL of
0.5% Triton X-100 in a microcentrifuge tube and vortexed for
1 min. The microcentrifuge tube was transferred to a 37 °C
incubator for 1 h. Triton X-100 is a surfactant that lyses
liposomes. Then, 200 μL of the siRNA containing Triton X-100
solution was homogeneously mixed with 200 μL of 200-fold
diluted Quant-iT RiboGreen RNA reagent working solution for
5 min. Resulting mixture solution was added to at least three
wells for each sample of a ﬂat bottom 96-well cell culture plate
and measured for ﬂuorescence. The 0.5% Triton X-100 solution
mixed with 200-fold diluted Quant-iT RiboGreen RNA reagent
working solution was used as a blank control. The
encapsulation eﬃciency is calculated from the following
formula: encapsulated siRNA concentration/initial siRNA
concentration ×100.
siRNA Sustained Release in Diﬀerent pH. Release of
siRNA from aCXCR4-Lcn2-pH and aCXCR4-Lcn2-LP were
measured in PBS at pH 5.5 and 7.4 at 37 °C. pH value of PBS
was adjusted by 1 M HCl. The aCXCR4-Lcn2-pH or aCXCR4-
Lcn2-LP solution (1 mL, siRNA: 0.36 μM) was added to a
FLOAT-A-LYZER G2 dialysis tubing (MWCO 300 kDa) and
dialyzed in 30 mL of PBS (pH 5.5 or 7.4) at 37 °C on a shaker
(100 rpm). 100 μL samples were collected from the solution
outside the dialysis tube at diﬀerent time points, and the siRNA
concentration was quantiﬁed with Quant-iT RNA Assay Kit on
a SpectraMaxGEMIN XPS ﬂuorescence spectrophotometer
(Molecular Devices Corp, Sunnyvale, CA).
Liposome Binding. HCC1500, MDA-MB-175VII, MDA-
MB-436, MDA-MB-231, and MCF10A cells were seeded on 6-
well plates at a density of 3 × 105 cells/well overnight. Then
cells were incubated for 4 h at 37 °C with (1) rhodamine-dextran
encapsulated nonspeciﬁc (IgG) liposome (IgG-RD-pH) and (2)
aCXCR4-RD-pH at a concentration of 1 μmol lipid/106 cells.
Then liposome binding eﬃciency was evaluated by ﬂow cytometer
a n da n a l y z e dw i t hF l o w J os o f t w a r e .T h ef o l d - o v e rI g G - R D - p H
value was calculated by dividing the mean ﬂuorescence intensity of
aCXCR4-RD-pH stained cells by that of the IgG-RD-pH stained
cells.
Cell-Liposome Immunoﬂuorescent Staining. Immuno-
ﬂuorescent staining was performed as described previously in
CXCR4 immunoﬂuorescent staining section. Instead of using
aCXCR4 antibody, cells were incubated for 4 h at 37 °C with
(1) IgG-RD-pHs and (2) aCXCR4-RD-pHs, respectively.
Lcn2 siRNA Knockdown. 106 cells (HCC1500, MDA-MB-
175VII, and MCF10A) or 105 cells (MDA-MB-436 and MDA-
MB-231) were seeded in 6-well plates and incubated for 24 h.
Cells were treated with (1) PBS; (2) naked siRNA; (3)
aCXCR4-pH without siRNA; (4) aCXCR4-SCR-pH; (5) Lcn2-
LIPO; (6) IgG-Lcn2-pH; (7) aCXCR4-Lcn2-LP; and (8)
aCXCR4-Lcn2-pH for 6 h at the siRNA concentration of
72 pmol/106 cells (equivalent lipid concentration: 1 μmol/106
cells for aCXCR-pH, aCXCR-SCR-pH, IgG-Lcn2-pH, and
aCXCR4-Lcn2-pH; 2.25 μmol/106 cells for aCXCR-Lcn2-LP;
0.5 μmol/106 cells for Lcn2-LIPO). Cells were rinsed three
times with PBS and further grown for 72 h. Lcn2 gene
expression was determined by qRT-PCR.
In the liposome concentration dependence tests, MDA-MB-
436 and MDA-MB-231 cells were treated with aCXCR4-Lcn2-
pH for 6 h at three diﬀerent lipid concentrations: 0.25, 0.5, and
1 μmol/106 cells. The siRNA concentration was diﬀerent
between samples: aCXCR4-Lcn2-pH, aCXCR4-SCR-pH, and
Lcn2-LIPO had 72, 70, and 140 pmol per μmol of lipid,
respectively. Cells were rinsed three times with PBS and further
grown for 72 h. The Lcn2 gene expression was examined by
qRT-PCR.
Cell Migration. Two aggressive MBC cells, MDA-MB-436
and MDA-MB-231, were treated with (1) PBS; (2) naked
siRNA; (3) aCXCR4-pH without siRNA; (4) aCXCR4-SCR-
pH; (5) Lcn2-LIPO; (6) IgG-Lcn2-pH; (7) aCXCR4-Lcn2-LP;
and (8) aCXCR4-Lcn2-pH for 6 h at the siRNA concentration
of 72 pmol/106 cells. Cells were rinsed three times with PBS
and further grown for 72 h. MDA-MB-436 (105 cell per well)
or MDA-MB-231 (50,000 cell per well) cells were seeded onto
COSTAR Transwell insert with permeable support polycar-
bonate membrane with 8 μm pore size in a 24-well plate.
DMEM without or with 10% fetal bovine serum was added to
the upper and lower wells respectively. Cells were incubated
and allowed to migrate for 20 h. Then cells on the reverse side
of the Transwell membrane facing the lower chamber after
transmigrating through the 8 μm pores of the Transwell
membrane were stained with Diﬀ-Quik Stain Set. Three ﬁelds
were counted for each sample.
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and MDA-MB-231 cells were treated with aCXCR4-Lcn2-pH
for 6 h at three diﬀerent lipid concentrations: 0.25, 0.5, and
1 μmol/106 cells. Cells were rinsed three times with PBS and
further grown for 72 h. Cell migration was examined by
Transwell migration assay as described above.
Cytotoxicity. In liposome concentration dependence tests,
MDA-MB-436 and MDA-MB-231 cells were treated with
aCXCR4-Lcn2-pH for 6 h at three diﬀerent lipid concen-
trations: 0.25, 0.5, and 1 μmol/106 cells. Cells were rinsed three
times with PBS and further grown for 72 h. The cytotoxicity of
liposome treated cells was evaluated by Dojindo cytotoxicity
assay with the manufacturer’s protocol.
Statistical Analysis. Data were measured in at least
triplicate and presented as mean ± standard deviation.
Statistical analysis was performed by using Student’s t-test.
P values <0.05 were considered statistically signiﬁcant.
■ RESULTS AND DISCUSSION
CXCR4 was previously identiﬁed as being signiﬁcantly
overexpressed in human breast tumor samples by immunohis-
tochemical staining (IHC).
31 In our study, we characterized the
CXCR4 gene and surface expression in four MBC cell lines:
HCC1500, MDA-MB-175VII, MDA-MB-436, and MDA-MB-
231. HCC1500 is estrogen receptor (ER)+/progesterone
receptor (PR)+/HER2−; MDA-MB-175VII is ER+/PR−/
HER2−; and MDA-MB-436 and MDA-MB-231 are triple-
negative (ER−/PR−/HER2−). The non-neoplastic mammary
epithelial cell line, MCF10A, was used as a control. CXCR4 gene
expression was quantiﬁed relative to MCF10A by qRT-PCR. As
shown in Figure 1A, HCC1500, MDA-MB-175VII, MDA-MB-
436, and MDA-MB-231 exhibited 10-, 2.5-, 3.7-, and 2.8-fold
higher CXCR4 gene expression than MCF10A, respectively.
The CXCR4 surface density was quantiﬁed via ﬂow cytometry
using a microbead assay (Table 1).
32 Similar to their CXCR4 gene
expression levels, MBC cell lines demonstrated signiﬁcantly higher
CXCR4 surface expression than MCF10A. CXCR4 surface
expression in HCC1500 and MDA-MB-175VII was over 20-fold
higher than MCF10A. The most aggressive, triple-negative MDA-
MB-231 cells had considerably less CXCR4 surface expression
than both HCC1500 and MDA-MB-175VII cells. This suggested
that MBC aggressiveness may be independent of the CXCR4
surface density.
CXCR4 surface expression in MBC cells was further
conﬁrmed via immunoﬂuorescent staining. Representative
micrographs illustrated greater CXCR4 surface expression on
HCC1500, MDA-MB-175VII, MDA-MB-436, and MDA-MB-
231 (Figure 1B−M) relative to MCF10A (Figure 1N−P).
These data conﬁrm that CXCR4 is overexpressed on the cell
surface of MBC cells but not non-neoplastic MCF10A cells.
CXCR4 expression in leukocytes, endothelial cells, and hema-
topoietic stem cells is lower than cancer cells.
33−37 Therefore,
CXCR4 may be a novel and desirable target for MBC cells. We
have shown previously that CXCR4 surface expressionnot gene
expressionwas a better predictor of in vitro liposome binding.
38
We engineered CXCR4-targeting, Lcn2 siRNA-encapsulating,
pH-responsive liposomes to test our synergistic therapeutic hypo-
thesis. A schematic diagram is shown in Figure 2. pH-responsive
liposomes are composed of a mixture of 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 1,2-dioleoyl-3-dimethylammonium-
propane (DODAP, pKa 6.6
39), and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine-N-dodecanoyl (N-dod-PE) (65:30:5,
mol:mol:mol). Liposomes incor p o r a t i n gD O D A Pr e s p o n dt ot h e
Figure 1. Characterization of CXCR4 gene and surface expression on
metastatic breast cancer and normal breast epithelial cells. CXCR4 gene
expression was quantiﬁed by qRT-PCR in panel A. CXCR4 fold change is
relative to GAPDH (*** p < 0.001). Panels B−P are representative
confocal ﬂuorescence microscope images of CXCR4 immunoﬂuorescent
staining in HCC1500 (B−D); MDA-MB-175VII (E−G); MDA-MB-436
(H−J); MDA-MB-231 (K−M); and MCF10A (N−P). DAPI was used to
stained the cell nuclei; mouse anti-human CXCR4 antibody (primary)
and goat anti-mouse NL557 antibody (secondary) were used to stain
CXCR4. All scale bars in panels B−Pr e p r e s e n t2 0μm.
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40,41 by increasing their cationic
character, fusing with the endosomal membrane, and delivering
the encapsulated siRNA within the cytoplasm.
29 N-dod-PE was
selected as the anchor for either an anti-CXCR4 antibody
(aCXCR4) or a nonspeciﬁc immunoglobulin G (IgG) con-
jugation. EDC/NHS chemistry was used to covalently bond the
carboxylic acid on N-dod-PE to a primary amine group present on
aCXCR4 or IgG, which is a widely used approach to modify
liposomes.
42 Conjugated aCXCR4 antibodies can target liposomes
speciﬁcally to CXCR4 overexpressing MBC cells and simulta-
neously inhibit the CXCR4 chemokine axis. siGENOME
SMARTpool human Lcn2 siRNA was encapsulated within the
liposome by directly mixing siRNA solubilized in PBS with the dry
lipid ﬁlm during liposome preparation. A nonresponsive liposome
comprised of DOPC:N-dod-PE (95:5, mol:mol) was used as a
control.
Liposome formulations were prepared and tested to compare
the eﬃcacy of siRNA delivery: (1) aCXCR4-targeted, Lcn2
siRNA encapsulating, pH-responsive liposome (aCXCR4-Lcn2-pH);
(2) aCXCR4-targeted, Lcn2 siRNA encapsulating, nonresponsive
liposome (aCXCR4-Lcn2-LP); (3) CXCR4-targeted, scrambled
siRNA encapsulating, pH sensitive liposomes (aCXCR4-SCR-pH);
and (4) Lcn2 siRNA encapsulating, Lipofectamine complexes
(Lcn2-LIPO). aCXCR4-Lcn2-LP and aCXCR4-SCR-pH were
used as negative controls, and Lcn2-LIPO was a positive control.
Their physical characteristics are shown in Table 2. The
hydrodynamic diameters of aCXCR4-Lcn2-pH, aCXCR4-Lcn2-LP,
aCXCR4-SCR-pH, and Lcn2-LIPO were 132 ± 4, 103 ± 2,
134 ± 3, and 703 ± 345 nm, respectively, as determined by dynamic
light scattering (DLS). Liposomes with diameters of less than
200 nm are ideal for intravenous administration due to their en-
hanced permeability and retention (EPR) within tumors.
39 The
polydispersity index (PDI) of all three extruded liposomes was less
than 0.1, demonstrating uniformity. Lipofectamine complexes are
routinely larger and less uniform due to the aggregation of cationic
molecules with negatively charged siRNA.
43 The zeta potentials of
aCXCR4-Lcn2-pH and aCXCR4-Lcn2-LP were −5.4 ± 1.4 and
−2.4 ± 0.4 mV, respectively, which were close to neutral charge. The
siRNA encapsulation eﬃciencies of aCXCR4-Lcn2-pH (36 ± 4%)
and aCXCR4-SCR-pH (35 ± 6%) were signiﬁcantly higher than
that of aCXCR4-Lcn2-LP (16 ± 7%). Lcn2-LIPO had a higher
encapsulation eﬃciency of 70 ± 2%. The antibody surface density
was 2,200 ± 190 molecules/μm2 for aCXCR4-Lcn2-pH and
aCXCR4-SCR-pH compared to 1,720 ± 20 molecules/μm2 for
aCXCR4-Lcn2-LP. aCXCR4-SCR-pH had similar parameters to
aCXCR4-Lcn2-pH due to the same liposome composition, albeit
with the exception of loaded siRNA.
Release proﬁles of Lcn2 siRNA from aCXCR4-Lcn2-pH and
aCXCR4-Lcn2-LP were determined by measuring the siRNA
Table 1. CXCR4 Surface Density on MBC Cells
HCC1500 MDA-MB-175VII MDA-MB-436 MDA-MB-231 MCF10A
CXCR4 (molecules/cell) 104,600 ± 680 110,000 ± 1,000 59,000 ± 1,400 15,000 ± 1,000 4,600 ± 100
Figure 2. Schematic diagram of aCXCR4-Lcn2-pH.
Table 2. Diameter, Size Distribution, Zeta Potential, siRNA Loading, and Antibody Density of Prepared Liposomes
sample size (nm) polydispersity index zeta potential (mV) encapsulation eﬃciency (%) aCXCR4 antibody density (molecules/μm2)
aCXCR4-Lcn2-pH 132 ± 4 0.05 −5.4 ± 1.4 36 ± 4 2,200 ± 190
aCXCR4-Lcn2-LP 103 ± 2 0.06 −2.4 ± 0.4 16 ± 7 1,720 ± 20
aCXCR4-SCR-pH 134 ± 3 0.04 −4.3 ± 0.2 35 ± 6 2,200 ± 190
Lcn2-LIPO 703 ± 345 0.273 −3.4 ± 2.5 70 ± 2 N/A
Figure 3. Cumulative siRNA releases from aCXCR4-Lcn2-pH (●) and aCXCR4-Lcn2-LP (○) in pH 7.4 (A) and pH 5.5 (B) buﬀers at 37 °C.
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Information). At pH 7.4, 50% of Lcn2 siRNA was released in
75 min from aCXCR4-Lcn2-pH, whereas it took 170 min for
50% of Lcn2 siRNA to be released from aCXCR4-Lcn2-LP.
Similar results were obtained at pH 5.5. In the absence of a
membrane with which to fuse,
26 siRNA release from aCXCR4-
Lcn2-pH and aCXCR4-Lcn2-LP was independent of pH.
We have previously demonstrated that this pH-responsive
formulation could successfully deliver siRNA to HeLa and
HUVEC cells in comparison with nonresponsive liposomes.
26
In addition, the zeta-potential of aCXCR4-Lcn2-pH changed from
−5.4 ± 1.4 mV (pH 7.4) to 13.9 ± 0.6 mV (pH 5.5); whereas that
of aCXCR4-Lcn2-LP merely changed from −2.4 ± 0.4 mV
(pH 7.4) to 0.6 ± 1.9 mV (pH 5.5). The increased cationic
character of the aCXCR4-Lcn2-pH liposomes may result in
electrostatic interactions between the siRNA and lipids, limiting
their ability to dialyze through the membrane.
Quantiﬁcation of liposome binding to MBC cells was
performed to evaluate the targeting eﬀectiveness of aCXCR4-
conjugated liposomes. In this study, aCXCR4 antibody or IgG
labeled, rhodamine dextran (RD) encapsulating, pH-responsive
liposomes (aCXCR4-RD-pH or IgG-RD-pH) were prepared
and used to quantitatively assess the MBC cellular binding and
uptake of liposomes by ﬂow cytometry. As shown in Figure 4A,
HCC1500, MDA-MB-175VII, MDA-MB-436, and MDA-MB-
231 cells demonstrated 2-, 2.9-, 2.3-, and 1.7-fold higher
binding of CXCR4-targeted liposomes diluted in medium
containing 10% serum relative to nonspeciﬁc IgG labeled
liposomes, respectively. No diﬀerence was observed in
MCF10A cells. Representative micrographs illustrate high
aCXCR4-RD-pH binding on HCC1500, MDA-MB-175VII,
MDA-MB-436, and MDA-MB-231 (Figure 4B−M) and low
aCXCR4-RD-pH binding on MCF10A (Figures 4N−P). The
shape and morphology of cell nuclei and whole cells are shown
in blue and green ﬂuorescence, respectively. The images
indicate rounded and elongated cell morphologies. Rhodamine-
dextran from aCXCR4-RD-pH is indicated by red ﬂuorescence.
In MBC cells (Figure 4B−M), red and green signals are
overlapping. This suggests the release of the rhodamine-dextran
Figure 4. (A) Cellular binding of immunoliposomes in HCC1500,
MDA-MB-175VII, MDA-MB-436, MDA-MB-231, and MCF10A.
Cells were treated with aCXCR4-RD-pH and IgG-RD- pH (control)
and then characterized via ﬂow cytometry (*** p < 0.001). Panels
B−P are representative confocal ﬂuorescent microscope images of
immunoliposome cellular binding in HCC1500 (B−D), MDA-MB-
175VII (E−G), MDA-MB-436 (H−J), MDA-MB-231 (K−M), and
MCF10A (N−P). DAPI and CellTracker Green were used to stain cell
nuclei and cytoplasm, respectively. All scale bars in panels B−P
represent 20 μm.
Figure 5. Lcn2 gene expression in MDA-MB-175VII, MDA-MB-436,
HCC1500, MDA-MB-231, and MCF10A cells as quantiﬁed by RT-
qPCR. Lcn2 fold change is relative to GAPDH (*** p < 0.001).
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cytoplasm. These results demonstrated that aCXCR4-RD-pH
liposomes targeted MBC cells, not non-neoplastic cells. This
was consistent with the high CXCR4 surface densities
measured on MBC cells relative to MCF10A (Table 1).
In addition to targeting CXCR4, pH-triggered siRNA
delivery was employed to silence the Lcn2 gene in MBC
cells. The silencing eﬀect was quantiﬁed by qRT-PCR. Figure 5
depicts endogenous Lcn2 expression in MBC cells before siRNA
knockdown. MDA-MB-175VII, MDA-MB-436, HCC1500, and
MDA-MB-231 exhibited 96-, 34-, 4.2-, and 4.9-fold higher Lcn2
gene expression than MCF10A, respectively. MBC cells were
dosed for 6 h with aCXCR4-Lcn2-pH, rinsed, and then incubated
for 72 h. MBC cells treated with aCXCR4-Lcn2-pH were
compared to cells treated with PBS, naked Lcn2 siRNA, CXCR4-
targeting, pH-responsive liposomes without Lcn2 siRNA
(aCXCR4-pH), aCXCR4-SCR-pH, IgG-labeled, pH-responsive
liposomes (IgG-Lcn2-pH), Lcn2-LIPO, and nonresponsive
aCXCR4-Lcn2-LP at an equivalent siRNA concentration of
72 pmol per 106 cells. As shown in Figure 6A−D, MBC cells
t r e a t e dw i t ha C X C R 4 - L c n 2 - p Hd e m o n s t r a t e dt h em a x i m u mL c n 2
gene knockdown: 78% for HCC1500, 65% for MDA-MB-175VII,
78% for MDA-MB-436, and 84% for MDA-MB-231. By compari-
son with the commercial siRNA transfection reagent, Lcn2-LIPO
demonstrated lower gene knockdown (65% for HCC1500, 20%
for MDA-MB-175VII, 51% for MDA-MB-436, and 30% for MDA-
MB-231) after the 6 h dosing. MBC cells treated with
nonresponsive aCXCR4-Lcn2-LP demonstrated knockdown in
the range of 35−58%; this suggested that the pH-sensitive
liposome is advantageous in siRNA delivery. MBC cells treated
with nonspeciﬁc IgG-Lcn2-pH alone showed a 22−45% Lcn2
knockdown, signiﬁcantly lower than those of CXCR4-targeted,
pH-triggered, siRNA encapsulating liposomes. Similar to naked
siRNA, aCXCR4-pH (without siRNA) and aCXCR4-SCR-pH
(with nontargeting siRNA) demonstrated no signiﬁcant reduction
in Lcn2 expression, which conﬁrmed that the CXCR4-CXCL12
axis blockade is independent of Lcn2 gene expression. The
signiﬁcant and eﬃcient decrease in Lcn2 expression by aCXCR4-
Lcn2-pH was achieved by employing both CXCR4 targeting and a
pH-responsive nanocarrier.
We evaluated the synergistic eﬀect of targeted Lcn2 siRNA
delivery and CXCR4 chemokine axis blockade on MBC cell
migration in vitro. Two aggressive triple-negative MBC cell
lines, MDA-MB-436 and MDA-MB-231, were selected to test
Figure 6. siRNA knockdown of Lcn2 gene expression in (A) HCC1500, (B) MDA-MB-175VII, (C) MDA-MB-436, and (D) MDA-MB-231 (NS:
no signiﬁcant diﬀerence, * p < 0.05, *** p < 0.001).
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assay. As shown in Figure 7, the number of migrated cells was
signiﬁcantly reduced in cells treated with aCXCR4-Lcn2-pH by
88% (MDA-MB-436) and 92% (MDA-MB-231) compared
with untreated cells. This result is signiﬁcantly higher than that
achieved by the commercial transfection reagent Lipofectamine
(Lcn2-LIPO, 35−38% inhibition). Cells treated with non-
responsive aCXCR4-Lcn2-LP exhibited a 58% (MDA-MB-436)
and a 77% (MDA-MB-231) decrease. No signiﬁcant changes in
cell migration were observed in cells treated with PBS and
naked siRNA. These results are consistent with the siRNA
knockdown study (Figure 6). Cells treated with aCXCR4-pH,
aCXCR4-SCR-pH, and IgG-Lcn2-pH demonstrated 16−18%,
9−10%, and 21−62% reductions in cell migration, respectively.
Targeting the Lcn2 siRNA via the CXCR4 receptor was more
eﬀective in reducing cell migration than the use of the pH-
responsive liposome (aCXCR4-Lcn2-LP vs IgG-Lcn2-pH).
These data indicate that the combination of targeting and
inhibition of CXCR4 and silencing of Lcn2 via aCXCR4-Lcn2-
pH more eﬀectively and synergistically impeded breast cancer
cell migration than subverting a single migration pathway,
either by knockdown of Lcn2 or inhibition of CXCR4 alone.
Since metastasis inversely correlates with patient survival, a
therapeutic directed at blocking multiple migratory pathways
may prolong life.
aCXCR4-Lcn2-pH was selected as the optimal formulation
for inhibiting MBC cell migration. First, we investigated the
cytotoxicity of aCXCR4-Lcn2-pH in MDA-MB-436 and MDA-
MB-231 cells via the Dojindo assay at equivalent lipid
concentrations: 1, 0.5, and 0.25 μmol per 106 cells. aCXCR4-
SCR-pH and Lcn2-LIPO were also studied. As shown in
Figure 8A,B, no cytotoxicity was observed at all three lipid
concentrations. The siRNA concentration was diﬀerent
between samples: aCXCR4-Lcn2-pH, aCXCR4-SCR-pH, and
Lcn2-LIPO had 72, 70, and 140 μmol/mol lipid, respectively.
Second, we determined the impact of the aCXCR4-Lcn2-pH
concentration on Lcn2 gene knockdown (Figure 8C,D). A
dose-dependent response was observed: Lcn2 gene expression
decreased as the concentration of aCXCR4-Lcn2-pH increased.
aCXCR4-Lcn2-pH at 1 μmol/106 cells (highest lipid concentration)
demonstrated the highest Lcn2 gene knockdown eﬃciencies
(78% for MDA-MB-436 and 84% for MDA-MB-231). Third, we
Figure 7. MDA-MB-436 (A) and MDA-MB-231 (B) cell migration were evaluated by Transwell migration assay. Both cells were incubated with
PBS, naked siRNA, aCXCR4-pH, aCXCR4-SCR-pH, Lcn2-LIPO, IgG-Lcn2-pH, aCXCR4-Lcn2-LP, and aCXCR4-Lcn2-pH. Representative
micrographs demonstrate MDA-MB-436 and MDA-MB-231 cells incubated with PBS (C and G), aCXCR4-pH (D and H), IgG-Lcn2-pH (E and I),
and aCXCR4-Lcn2-pH (F and J), after transmigrating through 8 μm pores of a Transwell membrane. Images taken were on the reverse side of the
membrane facing the lower chamber. All scale bars are 50 μm( * p < 0.05, ** p < 0.01, *** p < 0.001).
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aCXCR4-Lcn2-pH concentration. MBC cell migration inhibition
(Figure 8E,F) correlated with Lcn2 gene knockdown. aCXCR4-
Lcn2-pH at 1 μmol/106 cells demonstrated a 78−84% decrease in
Lcn2 expression and an 88−92% decrease in MBC cell migration.
The synergistic eﬀects produced by blocking both CXCR4 and
Lcn2 (Figure 7) may be due to the common signaling pathways
that are activated by both molecules. Lcn2 promotes MBC cell
migration by inducing the EMT.
15 The EMT has also been shown
to be one of the mechanisms via which CXCL12/CXCR4 regulates
breast cancer cell migration.
44 Evidence has suggested that CXCR4
may induce the EMT through the same transcription factor Slug as
does Lcn2.
45,46 In addition, Lcn2 has also been reported to promote
cancer cell migration by activating the Akt pathway,
47 which could
also be activated by CXCR4.
48 The main limitation of the
aCXCR4-Lcn2-pH approach would be unspeciﬁc binding to other
CXCR4-expressing cells, e.g., leukocytes, endothelial cells, and
hematopoietic stem cells. In the future, we will continue to
investigate this synergistic inhibition strategy for MBC therapy in
live animals.
■ CONCLUSIONS
We investigated the impact of simultaneous inhibition of
CXCR4 and Lcn2 pathways on MBC cell migration via
delivering CXCR4-targeted, pH-responsive liposomes encapsu-
lating Lcn2 siRNA to multiple MBC cell lines. By using this
method, the migration of two MBC cell lines, MDA-MB-436
and MDA-MB-231, was inhibited by 88% and 92%,
respectively. This result is signiﬁcantly more eﬃcient than
inhibition of the CXCR4 or Lcn2 pathway alone. Our results
indicated that a synergistic therapy involving multiple migration
pathways may be more successful than traditional therapies that
focus on a singular approach.
Figure 8. Lipid concentration dependence of MBC cell cytotoxicity (A and B), Lcn2 gene knockdown (C and D), and migration inhibition (E and F)
(NS: no signiﬁcant diﬀerence, *p < 0.05, ***p < 0.001).
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